A First-in Human, Phase 1 Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LY4336619, an Alkaline Phosphatase Placental-Like 2 (ALPPL2) T- Cell Engager Bispecific Antibody, in Adult Participants With Advanced Solid Tumors

Eli Lilly and Company

Summary

The main purpose of this study is to evaluate how safe and effective LY4336619 is in adults with advanced cancer. Some participants will receive LY4336619 alone, and some will receive it with another cancer medicine. Participants will be in the study for up to 2 years, depending on how they tolerate and respond to treatment.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Have histological diagnosis of locally advanced or metastatic solid tumor malignancy. * Have a life expectancy of at least 12 weeks as judged by the investigator. * Must be an appropriate candidate for study treatment. Study treatment is considered appropriate where approved measures are no longer effective or are not considered appropriate or safe in the opinion of the investigator, or the individual refuses the remaining most appropriate standard of care treatment. * Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale or Karnofsky…

Locations (23)

HonorHealth
Scottsdale, Arizona
City of Hope
Duarte, California
University of California, San Diego (UCSD) - Moores Cancer Center
La Jolla, California
The University of Chicago Medical Center (UCMC)
Chicago, Illinois
Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center
Boston, Massachusetts
South Texas Accelerated Research Therapeutics (START) - New York - Long Island
Lake Success, New York

Summary

Eligibility

Interventions

Locations (23)